Editorial Comment from Dr Chapple to Long‐term safety and efficacy of the novel β3‐adrenoreceptor agonist vibegron in Japanese patients with overactive bladder: A phase III prospective study
Abstract
This interesting manuscript by Yoshida et al. represents the long-term data on safety and efficacy of a new beta 3 agonist, vibegron 50 mg and 100 mg. This study shows the importance of dose titration, in that 30.2% of patients increased the dose up to 100 mg. An important feature of the data set is the low incidence of side effects which could be attributed to pharmacological action of the drug. These data are important, in that it provides additional information relating to the long-term use of a beta 3 agonist, albeit in an open label, non-controlled study. This mirrors the findings of the active controlled one year study with mirabegron previously reported. An important feature of this drug is the low incidence of drug–drug interaction. It is noted that adherence of all patients to the treatment was more than 75%. It is of interest that anticholinergics such as solifenacin, fesoterodine, imidafenacin and propiverine were used in combination with vibegron in 20.5% of patients overall with a similar prevalence of use in both the 50 and 100 mg groups. It was evident that the therapy produced significant changes from baseline in all overactive bladder symptoms and clearly this adds to the body of evidence suggesting that a beta 3 agonist is a useful new addition to the pharmacotherapeutic armamentarium. Although combination therapy with antimuscarinics is not yet licensed, clearly there is the potential for the increasing use of a beta 3 agonist in combination with…
Read the paper
Related studies
- Sarcopenia, sarcopenic overweight/obesity and risk of cardiovascular disease and cardiac arrhythmia: A cross-sectional study
- Workplace Violence Is Associated With Impaired Work Functioning in Nurses: An Italian Cross-Sectional Study
- Vagus Nerve Dysfunction in the Post-COVID-19 Condition: a pilot cross sectional study
- Association Between Metabolic Associated Fatty Liver Disease and Chronic Kidney Disease: A Cross-Sectional Study from NHANES 2017–2018
- Efficacy and safety of solifenacin succinate 10 mg once Daily: A multicenter, phase III, randomized, double-blind, placebo-controlled, parallel-group trial in patients with overactive bladder
- Association between triglyceride glucose‐body mass index and hypertension in Chinese adults: A cross‐sectional study
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.